Cite
Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.
MLA
Shah, Shreya A., et al. “Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.” Ophthalmology, vol. 131, no. 4, Apr. 2024, pp. 458–67. EBSCOhost, https://doi.org/10.1016/j.ophtha.2023.10.018.
APA
Shah, S. A., Amarikwa, L., Sears, C. M., Clauss, K. D., Rajjoub, R. D., Kang, J. Y., Tamhankar, M. A., Briceño, C. A., Harrison, A. R., Dosiou, C., Cockerham, K. P., Wester, S. T., Douglas, R. S., & Kossler, A. L. (2024). Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study. Ophthalmology, 131(4), 458–467. https://doi.org/10.1016/j.ophtha.2023.10.018
Chicago
Shah, Shreya A., Linus Amarikwa, Connie M. Sears, Kevin D. Clauss, Raneem D. Rajjoub, Julia Y. Kang, Madhura A. Tamhankar, et al. 2024. “Teprotumumab-Related Adverse Events in Thyroid Eye Disease: A Multicenter Study.” Ophthalmology 131 (4): 458–67. doi:10.1016/j.ophtha.2023.10.018.